Drug Trial Radar · NCT05961956
Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis
Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Actual
Start
Oct 12, 2023
Primary completion
Apr 18, 2026
Study completion Apr 18, 2026
Sponsor
- Lead sponsor
- Novadip BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, single arm, single-center clinical study to test NVDX3 in patients suffering from low grade one level degenerative lumbar (L1 - S1) spondylolisthesis. NVDX3 will be implanted during a single surgical intervention.
Conditions
- Degenerative Lumbar Spondylolisthesis
Interventions
NVDX3Drug
NVDX3 is implanted during a single surgical intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety EndpointTime frame: Up to 24 months post implant surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.